Significance, detection and markers of disseminated breast cancer cells.
暂无分享,去创建一个
[1] S. Braun,et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence , 2005, Cancer.
[2] David L Rimm,et al. Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer , 2005, Clinical Cancer Research.
[3] J. Schneider,et al. Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype , 2003, Breast Cancer Research.
[4] D. Mavroudis,et al. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse , 2004, International journal of cancer.
[5] R. Gelber,et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. Bastert,et al. Evaluating GA733-2 mRNA as a marker for the detection of micrometastatic breast cancer in peripheral blood and bone marrow , 1999, Archives of Gynecology and Obstetrics.
[7] D. Haagensen,et al. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. , 1983, The American journal of pathology.
[8] M. Neumaier,et al. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes , 1999, British Journal of Cancer.
[9] Qinghua Feng,et al. Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA. , 2004, Clinical chemistry.
[10] K. Pantel,et al. Detection and molecular characterisation of disseminated tumour cells: implications for anti-cancer therapy. , 2005, Biochimica et biophysica acta.
[11] Dieter Lutz,et al. Tumor cell detection in peripheral blood and bone marrow , 2006, Current opinion in oncology.
[12] S. Jaffer,et al. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Yuqiu Jiang,et al. Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays , 2002, Oncogene.
[14] J. Zidan,et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease , 2005, British Journal of Cancer.
[15] S. Riddell,et al. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. , 2006, Cancer research.
[16] G Leclercq,et al. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer , 2004, Molecular and Cellular Endocrinology.
[17] Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer , 2006, British Journal of Cancer.
[18] Mammaglobin a in breast cancer: Existence of multiple molecular forms , 2005, International journal of cancer.
[19] B. Gusterson,et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer , 1999, The Lancet.
[20] J. Izbicki,et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.
[21] D. Larsimont,et al. Establishment and characterization of three new breast‐cancer cell lines , 1998, International journal of cancer.
[22] G. T. Budd,et al. Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.
[23] M. Monden,et al. Mammaglobin B as a novel marker for detection of breast cancer micrometastases in axillary lymph nodes by reverse transcription‐polymerase chain reaction , 1999, Breast Cancer Research and Treatment.
[24] A. Giuliano,et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Martinelli,et al. Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer , 2004, Clinical Cancer Research.
[26] P. Ciborowski,et al. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: Potential role in metastasis , 2004, Clinical & Experimental Metastasis.
[27] J. Foekens,et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Y. Sagara,et al. Expression of maspin predicts poor prognosis in breast‐cancer patients , 2002, International journal of cancer.
[29] Niall O'Higgins,et al. Mammaglobin a: a promising marker for breast cancer. , 2002, Clinical chemistry.
[30] C. Caldas,et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Yixin Wang,et al. Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis. , 2005, The Journal of molecular diagnostics : JMD.
[32] Florian Fritzsche,et al. Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies , 2006, BMC Cancer.
[33] V. Eusebi,et al. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. , 2001, The American journal of pathology.
[34] Bjørn Naume,et al. Circulating and disseminated tumor cells. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Kober,et al. Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay. , 2004, Acta biochimica Polonica.
[36] G Kvalheim,et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M J O'Hare,et al. Linking gene expression patterns to therapeutic groups in breast cancer. , 2000, Cancer research.
[38] M. Reiss,et al. Detection and viability of tumor cells in peripheral blood stem cell and bone marrow collections from breast cancer patients. , 1994, Blood.
[39] J. Nesland,et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer , 2006, International journal of cancer.
[40] E. Osinaga,et al. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. , 2000, European journal of cancer.
[41] T. Fehm,et al. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] C. Hauser,et al. Changes in the Expression of Many Ets Family Transcription Factors and of Potential Target Genes in Normal Mammary Tissue and Tumors* , 2004, Journal of Biological Chemistry.
[43] D. Sidransky,et al. Nucleic acid-based methods for the detection of cancer. , 1997, Science.
[44] C. Klein,et al. Systemic Cancer Progression and Tumor Dormancy: Mathematical Models Meet Single Cell Genomics , 2006, Cell cycle.
[45] M. Dowsett,et al. Circulating tumour cells in breast cancer. , 2004, The Lancet. Oncology.
[46] B. Zehentner. Detection of disseminated tumor cells: strategies and diagnostic implications. , 2002, Expert review of molecular diagnostics.
[47] E. Kubista,et al. Circulating breast cancer cells are frequently apoptotic. , 2001, The American journal of pathology.
[48] RT-PCR for mammaglobin genes, MGB1 and MGB2, identifies breast cancer micrometastases in sentinel lymph nodes. , 2004, American journal of clinical pathology.
[49] H. Silva,et al. Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients. , 2006, European journal of cancer.
[50] G. Hortobagyi,et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] S. Braun,et al. Biological Characteristics of Micrometastatic Cancer Cells in Bone Marrow , 1999, Cancer and Metastasis Reviews.
[52] G. Dontu,et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. , 2006, Cancer research.
[53] M. Watson,et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. , 1999, Cancer research.
[54] M. Blumenberg,et al. Embryonic expression of the human 40-kD keratin: evidence from a processed pseudogene sequence. , 1988, American journal of human genetics.
[55] Anne Vincent-Salomon,et al. Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients , 2004, Clinical Cancer Research.
[56] I. Vlachonikolis,et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] D. Albertson,et al. Chromosome aberrations in solid tumors , 2003, Nature Genetics.
[58] M. Lacroix,et al. Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update , 2004, Breast Cancer Research and Treatment.
[59] G. Glinsky,et al. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.
[60] M. Monden,et al. NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors , 2004, Cancer Research.
[61] D. Jäger,et al. Antibodies and vaccines--hope or illusion? , 2005, Breast.
[62] I. Ellis,et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer , 2005, Modern Pathology.
[63] C. Jackisch,et al. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. , 1998, The American journal of pathology.
[64] William D. Foulkes,et al. Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .
[65] Guy Leclercq,et al. p53 and breast cancer, an update. , 2006, Endocrine-related cancer.
[66] H. Graham,et al. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years , 2005, International journal of cancer.
[67] C Hollmann,et al. DETECTION OF DISSEMINATED TUMOR CELLS IN PERIPHERAL BLOOD , 2005, Critical reviews in clinical laboratory sciences.
[68] H. Yoshida,et al. Expression of maspin is up‐regulated during the progression of mammary ductal carcinoma , 2003, Histopathology.
[69] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[70] J. Thiery,et al. Real‐time quantitative PCR determination of urokinase‐type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients , 2005, International journal of cancer.
[71] G. Bastert,et al. Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[72] T. Libermann,et al. PDEF, a Novel Prostate Epithelium-specific Ets Transcription Factor, Interacts with the Androgen Receptor and Activates Prostate-specific Antigen Gene Expression* , 2000, The Journal of Biological Chemistry.
[73] Joe W Gray,et al. Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. , 2003, Cancer cell.
[74] B. Glasgow,et al. Lipophilin, a novel heterodimeric protein of human tears , 1998, FEBS letters.
[75] R. Simmons,et al. Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients? , 2005, Journal of the American College of Surgeons.
[76] Jason L. Townson,et al. Dormancy of Solitary Metastatic Cells , 2006, Cell cycle.
[77] H Sommer,et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] M. Speicher,et al. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[79] A. Pileri,et al. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[80] S. Nakano,et al. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. , 2004, Surgery.
[81] Daniel Birnbaum,et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.
[82] K. Choi,et al. The detection of circulating breast cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. , 2000, Journal of Korean medical science.
[83] T. Eberlein,et al. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells , 2005, Breast Cancer Research and Treatment.
[84] N. Stoecklein,et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer , 2002, The Lancet.
[85] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[86] G. Ball,et al. High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.
[87] J. Klug,et al. Immunohistochemical analysis of secretoglobin SCGB 2A1 expression in human ocular glands and tissues , 2006, Histochemistry and Cell Biology.
[88] S. Wells,et al. Review of GCDFP‐15 An Apocrine Marker Protein , 1990, Annals of the New York Academy of Sciences.
[89] G. Bonadonna,et al. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients , 1978, Cancer.
[90] M. Hendrix,et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. , 1994, Science.
[91] D. Mavroudis,et al. Trastuzumab Administration Can Effectively Target Chemotherapy-Resistant Cytokeratin-19 Messenger RNA–Positive Tumor Cells in the Peripheral Blood and Bone Marrow of Patients With Breast Cancer , 2004, Clinical Cancer Research.
[92] L. Chow,et al. Detection of circulating breast cancer cells with multiple-marker RT-PCR assay. , 2001, Anticancer research.
[93] Homin K. Lee,et al. Coexpression analysis of human genes across many microarray data sets. , 2004, Genome research.
[94] W. Loo,et al. The value of bone marrow aspirates culture for the detection of bone marrow micrometastasis in breast cancer. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[95] R. Shiu,et al. Analysis of tissue- and hormone-specific regulation of the human prolactin-inducible protein/gross cystic disease fluid protein-15 gene in transgenic mice. , 1998, Journal of molecular endocrinology.
[96] B. Zehentner. Detection of disseminatedtumor cells: strategies and diagnostic implications , 2002 .
[97] N. Harbeck,et al. Comparative Analysis Between the HER2 Status in Primary Breast Cancer Tissue and the Detection of Isolated Tumor Cells in the Bone Marrow , 2004, Breast Cancer Research and Treatment.
[98] R. Eils,et al. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[99] W. Tian,et al. Expression of the prolactin‐indudble protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate , 2004, Cancer science.
[100] M. Ellis,et al. Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis , 2005 .
[101] E. Osinaga,et al. UDP‐N‐acetyl‐D‐galactosamine:polypeptide N‐acetylgalactosaminyltransferase 6 (ppGalNAc‐T6) mRNA as a potential new marker for detection of bone marrow‐disseminated breast cancer cells , 2006, International journal of cancer.
[102] Glen Kristiansen,et al. Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue , 2006, International journal of cancer.
[103] J. Nesland,et al. Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1 , 2004, Clinical Cancer Research.
[104] J. Zidan,et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] D. Jäger,et al. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. , 2002, Cancer immunity.
[106] R. Coombes,et al. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study , 1999, The Lancet.
[107] T. Fleming,et al. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes , 2004, Breast Cancer Research and Treatment.
[108] A. Nissan,et al. Multimarker RT–PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients , 2006, British Journal of Cancer.
[109] L. Murphy,et al. Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium. , 2002, Cancer research.
[110] Carlos Caldas,et al. Molecular Classification of Breast Carcinomas Using Tissue Microarrays , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[111] Jong-Hyeon Jeong,et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. , 2002, The New England journal of medicine.
[112] C. Perou,et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. , 2005, Cancer research.
[113] William C Reinhold,et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.
[114] W. Gillanders,et al. Quantitative real‐time RT‐PCR detection of breast cancer micrometastasis using a multigene marker panel , 2001, International journal of cancer.
[115] F. Bertucci,et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. , 2000, Human molecular genetics.
[116] E. Jaffee,et al. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. , 2005, Endocrine-related cancer.
[117] P. Friedman,et al. Identification and Immunohistochemical Characterization of a Mucin-Like Glycoprotein Expressed in Early Stage Breast Carcinoma , 2002, Tumor Biology.
[118] S. Indraccolo,et al. Dormant Tumors Awaken by a Short-Term Angiogenic Burst: The Spike Hypothesis , 2006, Cell cycle.
[119] M. Ligtenberg,et al. Suppression of cellular aggregation by high levels of episialin. , 1992, Cancer research.
[120] T. Reimer,et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] W. Hoffmann. Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. , 2005, Cellular and molecular life sciences : CMLS.
[122] S. Braun,et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence , 2001, Cancer.
[123] T. Fleming,et al. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. , 2004, Journal of the National Cancer Institute.
[124] J. Sohn,et al. Association of maspin expression with the high histological grade and lymphocyte‐rich stroma in early‐stage breast cancer , 2003, Histopathology.
[125] H. Soares,et al. Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis , 2004, Breast Cancer Research and Treatment.
[126] Peter Kuhn,et al. High speed detection of circulating tumor cells. , 2006, Biosensors & bioelectronics.
[127] Charles M. Perou,et al. A Comparison of Gene Expression Signatures from Breast Tumors and Breast Tissue Derived Cell Lines , 2002, Disease markers.
[128] O. Volpert,et al. Maspin is an angiogenesis inhibitor , 2000, Nature Medicine.
[129] G Leclercq,et al. A low-density DNA microarray for analysis of markers in breast cancer. , 2002, The International journal of biological markers.
[130] M. Watson,et al. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. , 1996, Cancer research.
[131] V. Chinchilli,et al. Detection of cancer cells in peripheral blood of breast cancer patients using reverse transcription-polymerase chain reaction for epidermal growth factor receptor. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[132] R. Coombes,et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] T. Fehm,et al. Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. , 2004, Anticancer research.
[134] D. Mavroudis,et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[135] G. Clark,et al. Maspin expression in invasive breast cancer: association with other prognostic factors , 2003, The Journal of pathology.
[136] W. Muller,et al. Addressing the Role of Cell Adhesion in Tumor Cell Dormancy , 2006, Cell cycle.
[137] T. Fehm,et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patients , 2006, Breast Cancer Research and Treatment.
[138] D. Amadori,et al. RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[139] R. Cote,et al. Detection of occult metastasis in patients with breast cancer. , 2001, Seminars in surgical oncology.
[140] T. Utsunomiya,et al. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. , 2005, International journal of oncology.
[141] C. Leaf,et al. Why we're losing the war on cancer (and how to win it). , 2004, Fortune.
[142] M L Lesser,et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] J. Dipersio,et al. Generation of CD8+ Cytotoxic T Lymphocytes Against Breast Cancer Cells by Stimulation with Mammaglobin-A-Pulsed Dendritic Cells , 2003, Breast Cancer Research and Treatment.
[144] Kornelia Polyak,et al. Do Myoepithelial Cells Hold the Key for Breast Tumor Progression? , 2005, Journal of Mammary Gland Biology and Neoplasia.
[145] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[146] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[147] Ming Zhang,et al. Tissue microarray analysis of maspin expression and its reverse correlation with mutant p53 in various tumors. , 2002, International journal of oncology.
[148] Ruud H. Brakenhoff,et al. Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.
[149] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[150] J. Klug,et al. Secretoglobin 2A1 is under selective androgen control mediated by a peculiar binding site for Sp family transcription factors. , 2005, Molecular endocrinology.
[151] H. Soares,et al. CK-19 Expression by RT-PCR in the Peripheral Blood of Breast Cancer Patients Correlates with Response to Chemotherapy , 2001, Breast Cancer Research and Treatment.
[152] L. Murphy,et al. Expression of the gene encoding a prolactin-inducible protein by human breast cancers in vivo: correlation with steroid receptor status. , 1987, Cancer research.
[153] I. Macdonald,et al. Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.
[154] D. Jäger,et al. Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases , 2006, Clinical Cancer Research.
[155] D. Felsher,et al. Tumor Dormancy: Death and Resurrection of Cancer As Seen through Transgenic Mouse Models , 2006, Cell cycle.
[156] D. Jäger,et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. , 2001, Cancer research.
[157] T. Dimpfl,et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.
[158] Tanja Fehm,et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[159] T. Fehm,et al. A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.
[160] L. Murphy,et al. Relationship between mammaglobin expression and estrogen receptor status in breast tumors , 2003, Endocrine.
[161] Holden T. Maecker,et al. Immune dysfunction and micrometastases in women with breast cancer , 2005, Breast Cancer Research and Treatment.
[162] Jonas S. Almeida,et al. An Innovative Microarray Strategy Identities Informative Molecular Markers for the Detection of Micrometastatic Breast Cancer , 2005, Clinical Cancer Research.
[163] G Leclercq,et al. Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. , 2004, Endocrine-related cancer.
[164] M. Dowsett,et al. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques , 2005, British Journal of Cancer.
[165] E. Hovig,et al. Ectopic expression of target genes may represent an inherent limitation of RT‐PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein gene EGP‐2 , 1997, International journal of cancer.
[166] Jose M. Silva,et al. Persistence of tumor DNA in plasma of breast cancer patients after mastectomy , 2002, Annals of Surgical Oncology.
[167] Alison Stopeck,et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[168] Tanja Fehm,et al. HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[169] R. Cote,et al. Detection and clinical importance of micrometastatic disease. , 1999, Journal of the National Cancer Institute.
[170] M. Fiegl,et al. Mammaglobin Gene Expression: A Superior Marker of Breast Cancer Cells in Peripheral Blood in Comparison to Epidermal-Growth-Factor Receptor and Cytokeratin-19 , 2000, Laboratory Investigation.
[171] A. Purushotham,et al. Putative markers for the detection of breast carcinoma cells in blood. , 1998, British Journal of Cancer.
[172] R K Jain,et al. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.
[173] G. Daley,et al. Novel role for PDEF in epithelial cell migration and invasion. , 2005, Cancer research.
[174] J. Köllermann,et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[175] J. Stec,et al. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. , 2005, Endocrine-related cancer.
[176] Barbara J. Trask,et al. Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes , 2004, Cancer Research.
[177] A. Giuliano,et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. , 2001, Cancer research.
[178] F. Rösel,et al. Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast , 2001, The Journal of pathology.
[179] M. Lacroix,et al. Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. , 2006, Current cancer drug targets.
[180] F. Kittrell,et al. Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. , 2001, Cancer research.
[181] J. Welsh,et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[182] J. R. Erickson,et al. Maspin Is an Intracellular Serpin That Partitions into Secretory Vesicles and Is Present at the Cell Surface , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[183] Thierry Maudelonde,et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. , 2005, Journal of immunological methods.
[184] M. Lacroix,et al. The “portrait” of hereditary breast cancer , 2005, Breast Cancer Research and Treatment.
[185] S. Reed,et al. Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. , 2002, Clinical chemistry.
[186] P. Friedman,et al. Evaluation of expression based markers for the detection of breast cancer cells , 2006, Breast Cancer Research and Treatment.
[187] D. L. Diamond,et al. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. , 2002, Biochemistry.
[188] M. Widschwendter,et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. , 2003, Cancer research.
[189] H. Sommer,et al. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen–Friedenreich tumor antigen , 2005, Histochemistry and Cell Biology.
[190] Peter Schraml,et al. Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.
[191] K. Cowan,et al. Detection of circulating tumor cells and micrometastases in Stage II, III, and IV breast cancer patients utilizing cytology and immunocytochemistry , 2000, Diagnostic cytopathology.
[192] M. Watson,et al. Identification of mammaglobin B, a novel member of the uteroglobin gene family. , 1998, Genomics.
[193] T. Godfrey,et al. A Rapid, Fully Automated, Molecular-Based Assay Accurately Analyzes Sentinel Lymph Nodes for the Presence of Metastatic Breast Cancer , 2006, Annals of surgery.
[194] I. Holen,et al. The detection of circulating breast cancer cells in blood , 2004, Journal of Clinical Pathology.
[195] Thomas Rau,et al. Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.
[196] K. Luzzi,et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. , 1998, The American journal of pathology.
[197] D. Hayes,et al. The measurement and therapeutic implications of circulating tumour cells in breast cancer , 2005, British Journal of Cancer.
[198] R. Marches,et al. Cancer Dormancy from Mice to Man: A Review , 2006, Cell cycle.
[199] M. Federico,et al. Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[200] International Study Group,et al. Prognostic importance of occult axillary lymph node micrometastases from breast cancers , 1990, The Lancet.
[201] H. M. Beier,et al. Uteroglobin/Clara Cell 10‐kDa Family of Proteins: Nomenclature Committee Report , 2000, Annals of the New York Academy of Sciences.
[202] J. Diamond,et al. Cytokeratin 20 is not a reliable molecular marker for occult breast cancer cell detection in hematological tissues , 2001, Breast Cancer Research and Treatment.
[203] S. Fox,et al. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. , 1997, Journal of the National Cancer Institute.
[204] E. van Marck,et al. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer , 2005, Breast Cancer Research.
[205] S. Braun,et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. , 2001, Cancer research.
[206] L. Kiesel,et al. HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients , 2006, Clinical Cancer Research.
[207] F. Bertucci,et al. Gene expression profiling of breast cell lines identifies potential new basal markers , 2006, Oncogene.
[208] Martin Widschwendter,et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. , 2005, Cancer research.
[209] Z. Shao,et al. The human myoepithelial cell is a natural tumor suppressor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[210] L. Akslen,et al. Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic Switch , 2006, Cell cycle.
[211] E. Kirkness,et al. A Novel Class of GABAA Receptor Subunit in Tissues of the Reproductive System* , 1997, The Journal of Biological Chemistry.
[212] J. Uhr,et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. , 2002, International journal of oncology.
[213] R. Eils,et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. , 2005, Cancer cell.
[214] E. Hovig,et al. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase‐polymerase chain reaction assays used to detect micrometastatic tumor cells , 1999, International journal of cancer.
[215] L. Chow,et al. Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[216] L. Tafra,et al. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. , 1998, Cancer research.
[217] J. Machiels,et al. Unreliability of carcinoembryonic antigen (CEA) reverse transcriptase-polymerase chain reaction (RT-PCR) in detecting contaminating breast cancer cells in peripheral blood stem cells due to induction of CEA by growth factors , 1999, Bone Marrow Transplantation.
[218] D. Jäger,et al. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. , 2005, Cancer immunity.
[219] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[220] L. Frati,et al. Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. , 2003, Oncology reports.
[221] William E Gillanders,et al. Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[222] M. Perraki,et al. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[223] Adam Kowalczyk,et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. , 2005, Cancer research.
[224] A. Jimeno,et al. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[225] Ajay N. Jain,et al. Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.
[226] Internationalludwigbreastcanc. Prognostic importance of occult axillary lymph node micrometastases from breast cancers , 1990 .
[227] G. Dontu,et al. Mammary stem cells, self-renewal pathways, and carcinogenesis , 2005, Breast Cancer Research.
[228] L. Bégin,et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.
[229] R. Zeillinger,et al. The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection. , 2005, Gynecologic oncology.
[230] P. Watson,et al. The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis , 1999, British Journal of Cancer.
[231] S. Roncella,et al. Relationship between human mammaglobin mRNA expression in breast cancer tissue and clinico-pathologic features of the tumors. , 2006, Journal of experimental & clinical cancer research : CR.
[232] Max S Wicha,et al. Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.
[233] R. Henriksson,et al. Secretoglobins in the human pituitary: high expression of lipophilin B and its down-regulation in pituitary adenomas , 2005, Acta Neuropathologica.
[234] A. Hill,et al. Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes , 2002, British Journal of Cancer.
[235] N. Davidson,et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. , 1993, Blood.
[236] E. Leygue,et al. Human small breast epithelial mucin: the promise of a new breast tumor biomarker. , 2004, DNA and cell biology.
[237] W. Gillanders,et al. Molecular analysis improves sensitivity of breast sentinel lymph node biopsy: results of a multi-institutional prospective cohort study. , 2005, Surgery.
[238] G. Stamp,et al. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co‐expressed in normal, hyperplastic, and neoplastic human breast epithelium , 1997, The Journal of pathology.
[239] P. Friedman,et al. Mammaglobin is found in breast tissue as a complex with BU101. , 2001, Biochemistry.
[240] A. Sood,et al. Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[241] K. Pillay,et al. An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes , 2006, Journal of Clinical Pathology.
[242] J. Aguirre-Ghiso,et al. Opposing Roles of Mitogenic and Stress Signaling Pathways in the Induction of Cancer Dormancy , 2006, Cell cycle.
[243] R. Gangnus,et al. Genomic Profiling of Viable and Proliferative Micrometastatic Cells from Early-Stage Breast Cancer Patients , 2004, Clinical Cancer Research.
[244] W. Loo,et al. Surgery‐related shedding of breast cancer cells as determined by RT‐PCR assay , 2003, Journal of surgical oncology.
[245] M. Provencio,et al. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[246] S. Sheng,et al. Tumor suppressive maspin and epithelial homeostasis , 2006, Journal of cellular biochemistry.
[247] I. Bièche,et al. Prognostic value of maspin mRNA expression in ERα-positive postmenopausal breast carcinomas , 2003, British Journal of Cancer.
[248] S. Braun,et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[249] Jason L. Townson,et al. Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases , 2003, Breast Cancer Research and Treatment.
[250] J. Kovarik,et al. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up , 1998, Breast Cancer Research and Treatment.
[251] M. Sopel,et al. Maspin and c-erbB-2 expression in correlation with microvessel density in invasive ductal breast cancer. , 2005, Folia histochemica et cytobiologica.
[252] J. Aguirre-Ghiso,et al. The Problem of Cancer Dormancy: Understanding the Basic Mechanisms and Identifying Therapeutic Opportunities , 2006, Cell cycle.
[253] J. Ingle,et al. Evaluation of a Panel of Tumor Markers for Molecular Detection of Circulating Cancer Cells in Women with Suspected Breast Cancer , 2005, Clinical Cancer Research.
[254] Ming Zhang,et al. Maspin Mediates Increased Tumor Cell Apoptosis upon Induction of the Mitochondrial Permeability Transition , 2005, Molecular and Cellular Biology.
[255] G. Viale,et al. Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA , 2006, Breast Cancer Research and Treatment.
[256] J. López-Guerrero,et al. Use of reverse-transcriptase polymerase chain reaction (RT-PCR) for carcinoembryonic antigen, cytokeratin 19, and maspin in the detection of tumor cells in leukapheresis products from patients with breast cancer: comparison with immunocytochemistry. , 1999, Journal of hematotherapy.
[257] Hyunsoo Kim,et al. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. , 2003, Archives of pathology & laboratory medicine.
[258] K. Pantel,et al. BM micrometastases and circulating tumor cells in breast cancer patients: where have we been, where are we now and where does the future lie? , 2005, Cytotherapy.
[259] E. Lee,et al. The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma , 2005, Cancer.
[260] K. Pienta,et al. Global gene expression profiling of circulating tumor cells. , 2005, Cancer research.
[261] L. Liotta,et al. Tumor invasion and metastasis: an imbalance of positive and negative regulation. , 1991, Cancer research.
[262] I. Wang,et al. Gene expression profiles in human nasal polyp tissues studied by means of DNA microarray. , 2004, The Journal of allergy and clinical immunology.
[263] A. Hart,et al. Molecular markers of breast cancer metastasis , 2005 .
[264] A. Rossi,et al. Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[265] J. Bergh,et al. Monitoring of disseminated tumor cells in bone marrow in high‐risk breast cancer patients treated with high‐dose chemotherapy , 2006, International journal of cancer.
[266] I. Vlachonikolis,et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[267] L. J. Veer,et al. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers , 2004, British Journal of Cancer.
[268] R. Orr,et al. Molecular Detection of Micrometastatic Breast Cancer in Histopathology-Negative Axillary Lymph Nodes Correlates With Traditional Predictors of Prognosis: An Interim Analysis of a Prospective Multi-Institutional Cohort Study , 2004, Annals of surgery.
[269] B. Matouš,et al. Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer. , 2004, Neoplasma.
[270] R. Hill. Identifying cancer stem cells in solid tumors: case not proven. , 2006, Cancer research.
[271] Guy Leclercq,et al. Molecular characterization of breast cancer cell lines by a low-density microarray. , 2005, International journal of oncology.